Loading
A phase 2 trial of TAS6417 in non-small-cell lung cancer, run by Taiho Oncology, Inc., now recruiting.
A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation. is a phase 2 interventional study registered as NCT05967689 by Taiho Oncology, Inc., with 220 participants planned, started 2023-07-31 and due to reach its primary completion in 2028-08-31. Interventions recorded: TAS6417, CYP Cocktail and Transporter Cocktail.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Araris Biotech (Taiho), Non-small-cell lung cancer and the tag pipeline.
Shares Araris Biotech (Taiho) and the tag pipeline.
Shares Araris Biotech (Taiho) and the tag pipeline.
Shares EGFR-mutated non-small-cell lung cancer, Non-small-cell lung cancer and the tag pipeline.
Shares EGFR-mutated non-small-cell lung cancer, Non-small-cell lung cancer and the tag pipeline.
Shares EGFR-mutated non-small-cell lung cancer, Non-small-cell lung cancer and the tag pipeline.
Shares EGFR-mutated non-small-cell lung cancer, Non-small-cell lung cancer and the tag pipeline.
Shares EGFR-mutated non-small-cell lung cancer, Non-small-cell lung cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/